LucasPye BIO
LucasPye BIO is a Philadelphia-based contract development and manufacturing organization (CDMO) that produces protein-therapeutic and viral-therapeutic drug products for biopharmaceutical clients. Founded in 2018, the privately-held company operates with 11-50 employees under founder and CEO Tia Lyles-Williams.
- Company typePrivate
- Founded2018
- HeadquartersPhiladelphia, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What LucasPye BIO does
LucasPye BIO is a privately-held Contract Development and Manufacturing Organization (CDMO) founded in 2018 and headquartered in Philadelphia, Pennsylvania. The company manufactures protein-therapeutic and viral-therapeutic drug products, placing it in the specialized biologics contract manufacturing segment of the pharmaceutical services industry. Its target customers are biopharmaceutical developers requiring contract production capacity for biologic and viral-based drug substances, including emerging gene therapy and protein-based therapeutic developers.
Operating with a small team of 11-50 employees, LucasPye BIO positions itself as a specialized service provider in an industry where cGMP-compliant biologics manufacturing capabilities are technically demanding and capital-intensive. The company's business model follows the standard CDMO fee-for-service structure, generating revenue through development and manufacturing contracts with biologic drug developers, though no specific pricing models, contract values, or customer relationships are disclosed in the source data.
The company is founder-led, with Tia Lyles-Williams serving as CEO and founder. Capital formation to date has been limited, with a single documented funding round of $1,000,000 raised in May 2019 from undisclosed investors. The absence of subsequent funding rounds, detailed product disclosures, customer references, or partnerships in the source data indicates that LucasPye BIO remains at an early operational stage relative to scaled CDMO competitors.
LucasPye BIO firmographics
Firmographics- Name
- LucasPye BIO
- Website
- https://lucaspyebio.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- LucasPye BIO is a Philadelphia-based contract development and manufacturing organization (CDMO) that produces protein-therapeutic and viral-therapeutic drug products for biopharmaceutical clients. Founded in 2018, the privately-held company operates with 11-50 employees under founder and CEO Tia Lyles-Williams.
- Ownership category
- akta.pro rank
LucasPye BIO industry classification
Industry- Product category
- Biopharmaceutical CDMO Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
Keywords
Where LucasPye BIO is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Markets served
LucasPye BIO business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
LucasPye BIO product offering
Product offeringCore offering
LucasPye BIO is a Contract Development and Manufacturing Organization (CDMO) that develops and manufactures protein-therapeutic and viral-therapeutic drug products on behalf of biopharmaceutical clients. The company delivers outsourced development and manufacturing services for biologic drug substances and drug products within its Philadelphia-based operations.
Differentiator
Problem solved
Functional benefit
Products and services
- Protein-Therapeutic Drug Product CDMO Services Contract development and manufacturing services for protein-based therapeutic drug products, delivered by LucasPye BIO to biopharmaceutical clients requiring outsourced biologics capacity.
- Viral-Therapeutic Drug Product CDMO Services Contract development and manufacturing services for viral-based therapeutic drug products, addressing sponsors needing specialized viral-therapeutic process and production capability.
Companies that use LucasPye BIO
Customer profileIdeal customer profiles1 record
LucasPye BIO technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
LucasPye BIO partnerships and signals
Strategic signalRecent moves3 records
LucasPye BIO competitors and assessment
Company assessmentDirect peers
- AGC Biologics: Global CDMO offering mammalian biologics and viral-vector manufacturing services across development and commercial scales. Directly competes with LucasPye BIO across protein therapeutics and gene-therapy drug substance manufacturing.
- Resilience: Biopharma manufacturing company focused on biologics, viral vectors, and cell therapies with modern GMP capacity. Competes with LucasPye BIO for emerging biotech sponsors seeking outsourced protein and viral-therapeutic manufacturing.
- Vibalogics: Specialized CDMO focused on viral vectors, viral vaccines, and viral-vector drug product manufacturing. Closely comparable to LucasPye BIO's viral-therapeutic drug product offering.
- Cobra Biologics (Charles River Laboratories): CDMO offering plasmid DNA, viral vector, and biologics development and manufacturing services. Direct competitor in the protein-therapeutic and viral-therapeutic CDMO space.
- Andelyn Biosciences: Specialty CDMO focused on viral vector and gene therapy manufacturing with clinical and commercial GMP capacity. Closely comparable to LucasPye BIO's viral-therapeutic drug product offering for cell and gene therapy sponsors.
- BioVectra: CDMO offering biologics and microbial fermentation services including plasmid and protein therapeutics. Comparable CDMO scale and modality mix to LucasPye BIO.
Broad incumbents
- Catalent: Large-scale global CDMO with deep biologics and viral-vector capabilities across drug substance and drug product. Overlaps with LucasPye BIO across protein and viral-therapeutic manufacturing, though at vastly greater scale.
- Lonza Biologics: World-leading CDMO with extensive mammalian and microbial biologics manufacturing services. Indirectly competes with LucasPye BIO for protein-therapeutic CDMO programs while serving much larger commercial sponsors.
- WuXi Biologics: Global biologics CDMO with end-to-end discovery, development, and manufacturing services. Operates in the same protein-therapeutic manufacturing category as LucasPye BIO at substantially greater scale.
- Thermo Fisher Scientific (Patheon CDMO): Diversified life sciences and CDMO services organization with biologics drug substance and drug product capabilities. Broad incumbent competing for outsourced protein-therapeutic manufacturing programs.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
LucasPye BIO social profiles
Digital presenceLucasPye BIO financial estimates
Financial estimateRevenue estimate
Valuation estimate
LucasPye BIO leadership team
Management profileNumber of profiles
Profiles1 record
LucasPye BIO funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LucasPye BIO M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LucasPye BIO
What does LucasPye BIO do?
LucasPye BIO is a Contract Development and Manufacturing Organization (CDMO) that develops and manufactures protein-therapeutic and viral-therapeutic drug products on behalf of biopharmaceutical clients. The company delivers outsourced development and manufacturing services for biologic drug substances and drug products within its Philadelphia-based operations.
Is LucasPye BIO a public or private company?
LucasPye BIO is a private company. It is classified as venture growth investor backed and is currently operating.
When was LucasPye BIO founded?
LucasPye BIO was founded in 2018. It employs 11 to 50 people.
Where is LucasPye BIO based?
LucasPye BIO is headquartered in Philadelphia, United States, in the North America region.
Who are LucasPye BIO's main competitors?
Direct peers on record are AGC Biologics, Resilience, Vibalogics, Cobra Biologics (Charles River Laboratories), Andelyn Biosciences and BioVectra. Broad incumbents are Catalent, Lonza Biologics, WuXi Biologics and Thermo Fisher Scientific (Patheon CDMO).
Does LucasPye BIO have an API?
No public API is recorded for LucasPye BIO.
What industry is LucasPye BIO in?
LucasPye BIO's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing). Its NAICS code is 325414 and its SIC code is 2836.